Trial Profile
Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 15 Mar 2017
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Guillain-Barre syndrome
- Focus Therapeutic Use
- Acronyms ICA-GBS
- Sponsors Alexion AstraZeneca Rare Disease
- 15 Mar 2017 Status changed from recruiting to discontinued.
- 06 Nov 2015 Accrual to date is 16% according to United Kingdom Clinical Research Network record
- 15 Nov 2014 Accrual to date is 3% according to United Kingdom Clinical Research Network record